Physician profile
Amit Barochia
NPI 1861615130
$5,594.95
in general payments reported to CMS, 2019-2025
48 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $1,174 · 2021: $1,213 · 2022: $1,036 · 2023: $202 · 2024: $141 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.69 |
| Education | $106.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $561.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $520.80 | 2019-2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $478.11 | 2019-2022 | |
| Janssen Biotech, INC. | $434.89 | 2019-2025 | Carvykti, Rybrevant |
| Celgene Corporation | $358.14 | 2019-2022 | |
| Seagen INC. | $310.67 | 2019-2023 | |
| Pfizer INC. | $289.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $265.42 | 2019-2021 | |
| Lilly USA, LLC | $236.23 | 2019-2024 | Verzenio |
| Genzyme Corporation | $186.80 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.20 | 2019-2022 | |
| Daiichi Sankyo INC. | $155.66 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $150.43 | 2019-2025 | Libtayo |
| Incyte Corporation | $141.83 | 2019-2021 | |
| Genentech USA, INC. | $128.83 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Barochia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.